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Abstract. A series of [1,2,4]triazino[4,3-a]indoles was prepared
in good yield by reacting 2-diazo-3-ethoxycarbonylindole with
methylene active compounds. Derivatives of the title ring system
were tested against a panel of 60 human tumor cell lines, and
showed inhibitory activity against a wide range of cancer cell lines
at micromolar concentration. 
As part of our ongoing program directed towards the design,
synthesis and evaluation of novel compounds of biological
interest containing the pyrrole and the indole moieties, we have
reported the synthesis of 2-diazopyrroles (1) and 2-diazoindoles
(2) which are versatile key intermediates for the synthesis of
biologically active compounds. In fact we synthesized 
2-triazenopyrroles and 2-triazenoindoles by reaction of the
corresponding diazo compounds with secondary amines. Such
compounds can be considered deaza analogues of dacarbazine,
a triazenoimidazole derivative used in therapy as the single
most active drug available for the treatment of malignant
melanoma (3). Biological screenings of both classes of
derivatives gave quite interesting results, especially those of the
pyrrole series. In fact one of them displayed cytotoxicity against
leukemia, lymphoma and carcinoma cell lines at micromolar
level (3.9-21.2) (4), while those of the indole series were less
active with GI50 in the range 23-99 ÌM (5).
By reacting 2-diazopyrroles with aryl or alkyl isocyanates,
we also obtained several derivatives of the new ring system
pyrrolo[2,1-d][1,2,3,5]tetrazine (6), a deaza analogue of the
antitumor drug temozolomide, today on the market under
the trade name TEMODAL® and used against malignant
melanoma, mycosis fungoides and brain tumors (7). The
synthesised pyrrolotetrazinones, tested in vitro against a
panel of 60 human cancer cell lines, showed potent
antiproliferative activity in the low micromolar or
submicromolar range, some of them reaching GI50 up to
nanomolar concentrations (8). 
Furthermore, upon reaction with the sodium salts of ‚-
diketones, ‚-carbonitriles, ‚-dinitriles and ‚-ketoesters, 2-
diazopyrroles afforded derivatives of the new ring system
pyrrolo[2,1-c][1,2,4] triazine that inhibited the growth of a
wide range of human cancer cell lines at micromolar
concentration (9). The title heterocyclic system contains the
1,2,4-triazine moiety, to which a wide range of biological
properties such as antibacterial, antibiotic, antiviral and
antitumor have been ascribed (10). In particular,
pyrazolo[5,1-c][1,2,4]triazine derivatives exhibited
antineoplastic activity against the mouse sarcoma 180 and
methylcolanthrene-induced rat sarcoma (11).
Encouraged by these results and considering the great
versatility of 2-diazoindoles, we thought it was interesting to
verify whether the condensation of the 1,2,4-triazine moiety
with the indole system increases the biological activity.
In this paper, we report a simple synthesis of the
[1,2,4]triazino[4,3-a]indole system based on the reaction of
2-diazoindole of type 1, obtained by diazotization of 2-
aminoindoles according to a method recently reported, (2)
with methylene active compounds. The reactions were
carried out in absolute ethanol at room temperature for 24
hours, with the sodium salts of type 2a-d prepared in situ
with sodium ethoxide in absolute ethanol. The primary
coupling products 3a-d, which are analogous with similar
compounds in the azole series (12) and exist in the hydrazo
form, were not isolated as they spontaneously cyclize to the
desired [1,2,4]triazino[4,3-a]indoles in good yields (72-80%)
(Figure 1). The structure of [1,2,4]triazino[4,3-a]indoles 4a-
d was confirmed by IR and NMR data as well as elemental
analysis. An evaluation of the spectroscopic data led to the
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Figure 1. Synthetic pathway for derivatives 4.
Figure 2. Hydrogen bondings in compounds 4.
conclusion that compounds 4a,c,d exist in the imino form.
Such a form is stabilized by the hydrogen bonding between
the hydrogen on the N-1 and the ethoxycarbonyl
functionality on position 10 of the triazinoindole ring
system. In the case of compounds 4c and 4d, an additional
hydrogen bonding of the imino hydrogen with the adjacent
carboxamido and ethoxycarbonyl moieties respectively,
further stabilizes the compounds in such a form (Figure 2).
On the other hand, in the azolo[1,2,4]triazine series, it has
already been observed that hydrogen bonding determined
the tautomer populations of the bicyclic systems (13).
In the case of compound 4b, the presence of the two
hydrogen bonds, analogous to those present in compounds
4c and 4d, stabilizes the hydrate form which can be isolated,
giving rise to a full aromatic system.
Materials and Methods
Chemistry. All melting points were taken on a Buchi-Tottoli
capillary apparatus and are uncorrected; IR spectra were
determined in bromoform with a Jasco FT/IR 5300
spectrophotometer; 1H and 13C NMR spectra were measured at
200 and 50.3 MHz, respectively, in DMSO-d6 (TMS as internal
reference), using a Bruker AC-E series 200 MHz spectrometer.
Column chromatography was performed with a BIOTAGE
FLASH40i chromatography module (prepacked polyethylene
cartridge system). For all new compounds, elemental analyses were
within ± 0.4% of theoretical values.
Preparation of 2-diazo-3-ethoxycarbonylindole (1). According to the
procedure described previously (2), to a stirred solution of 2-amino-
3-ethoxycarbonylindole (10 mmol) in acetic acid (80%, 10 mL) at
0ÆC, a solution of sodium nitrite (10 mmol) in the minimum
amount of water (2 mL) was added under a nitrogen atmosphere
and in the dark. The reaction mixture was stirred for 3 hours and
neutralised with an aqueous solution of sodium carbonate (10%),
keeping the temperature at 0ÆC. The brown solid separated was
filtered, dried in the dessicator under vacuum and in the dark. The
crude product was quickly washed with cyclohexane to give one
which furnished an IR spectrum identical to an authentic sample.
General method for the preparation of [1,2,4]triazino[4,3-a]indoles 4a-
d. To a solution of active methylene compounds 2a-d (2 mmol) in
anhydrous ethanol (50 mL), a solution of sodium ethoxide (2 mL,
1N) in anhydrous ethanol (10 mL) was added dropwise. The reaction
mixture was stirred at 0ÆC for 30 minutes then a solution of 2-diazo-
3-ethoxycarbonylindole 1 (2 mmol) in anhydrous ethanol was added
dropwise with stirring at 0ÆC. The mixture was stirred at room
temperature for an additional 24 hours, after which the solvent was
removed under reduced pressure, the residue taken up with water,
filtered and air dried. The crude [1,2,4]triazino[4,3-a]indoles were
purified by chromatography using dichloromethane: ethyl acetate
(9:1) as eluant, and recrystallized from ethanol.
Ethyl 3-cyano-4-imino-1,4-dihydro[1,2,4]triazino[4,3-a]indole-10-
carboxylate (4a), (yield 80%), mp >320ÆC; ir: 3296 (NH), 3209
(NH), 2229 (CN), 1675 (CO) cm-1; 1H nmr (ppm): 1.39 (3H, t,
J=6.8 Hz, CH3), 4.41 (2H, q, J=6.8 Hz, CH2), 7.37 (1H, t, J=7.5
Hz, H-7), 7.48 (1H, t, J=7.5 Hz, H-8), 8.10 (1H, d, J=7.5 Hz, H-6),
8.73 (1H, d, J=7.5 Hz, H-9), 8.80 (1H, vbs, C=NH), 11.50 (1H, vbs,
NH); 13C nmr (ppm): 14.1 (q), 59.8 (t), 90.3 (s), 113.9 (s), 116.5
(d), 119.7 (d), 123.0 (d), 123.4 (s), 125.4 (d), 126.1 (s), 129.3 (s),
138.3 (s), 143.9 (s), 163.1 (s).
Ethyl 3-acetyl-4-hydroxy-4-methyl-1,4-dihydro[1,2,4]triazino[4,3-
a]indole-10-carboxylate (4b), (yield 72%), mp 174-176ÆC; ir: 3449
(OH), 3284 (NH), 1671 (CO), 1614 (CO) cm-1; 1H nmr (ppm): 1.27
(3H, t, J=7.0 Hz, CH3), 2.02 (3H, s, CH3), 2.34 (3H, s, CH3), 4.26
(2H, q, J=7.0 Hz, CH2), 7.05 (1H, t, J=7.8 Hz, H-7), 7.12 (1H, t,
J=7.8 Hz, H-8), 7.37 (1H, s, OH), 7.69 (1H, d, J=7.8 Hz, H-6),
7.83 (1H, d, J=7.8 Hz, H-9), 11.70 (1H, s, NH);13C nmr (ppm):
14.7 (q), 25.1 (q), 26.6 (q), 59.0 (t), 78.8 (s), 85.0 (s), 113.6 (d),
119.7 (d), 121.2 (d), 122.4 (d), 126.0 (s), 130.4 (s), 137.1 (s), 140.1
(s), 163.9 (s), 194.7 (s).
Ethyl 3-(aminocarbonyl)-4-imino-1,4-dihydro[1,2,4]triazino[4,3-
a]indole-10-carboxylate (4c), (yield 80%), mp >320ÆC; ir: 3477
(NH), 3257-3165 (NH and NH2), 1676 (CO), 1607 (CO) cm
-1; 1H
nmr (ppm): 1.51 (3H, t, J=7.7 Hz, CH3), 4.51 (2H, q, J=7.7 Hz,
CH2), 7.45 (1H, t, J=7.7 Hz, H-7), 7.58 (1H, t, J=7.7 Hz, H-8),
7.90 (1H, bs, NH), 8.05 (1H, bs, NH), 8.25 (1H, d, J=7.7 Hz, H-6),
8.90 (1H, d, J=7.7 Hz, H-9), 10.70 (1H, vbs, C=NH), 12.01 (1H,
vbs, NH); 13C nmr (ppm): 14.1 (q), 59.0 (t), 116.3 (d), 119.1 (d),
121.7 (d), 124.1 (s), 124.7 (d), 126.4 (s), 128.9 (s), 139.9 (s), 144.8
(2xs), 163.0 (s), 166.0 (s).
Diethyl 4-imino-1,4-dihydro[1,2,4]triazino[4,3-a]indole-3,10-dicarboxylate
(4d), (yield 75%), mp >320ÆC; ir: 3341 (NH), 3301 (NH), 1697 (CO),
1674 (CO) cm-1; 1H nmr (ppm): 1.31 (3H, t, J=6.5 Hz, CH3), 1.34 (3H,
t, J=7.4 Hz, CH3), 4.31 (2H, q, J=6.5 Hz, CH2), 4.38 (2H, q, J=7.4
Hz, CH2), 7.30 (1H, t, J=8.3 Hz, H-7), 7.42 (1H, t, J=8.3 Hz, H-8),
8.08 (1H, d, J=8.3 Hz, H-6), 8.87 (1H, d, J=8.3 Hz, H-9), 9.40 (1H,
vbs, C=NH), 10.00 (1H, vbs, NH);13C nmr (ppm): 14.0 (q), 14.6 (q),
59.4 (t), 61.2 (t), 116.8 (s), 117.2 (d), 119.3 (d), 122.2 (d), 124.2 (s),
124.8 (d), 126.4 (s), 130.2 (s), 145.7 (2 x s), 163.0 (s), 163.8 (s).
Results and Discussion
The triazinoindoles 4c and 4d were selected by NCI and
their cytotoxicity was evaluated in in vitro disease-oriented
antitumor screenings (14) against a panel of 60 human
tumor cell lines derived from leukemia, non-small lung
cancer, colon cancer, CNS cancer, melanoma, ovarian
cancer, renal cancer, prostate cancer and breast cancer. The
test compounds were evaluated using five concentrations at
10-fold dilutions, the highest being 10-4 M and the others
10-5, 10-6, 10-7 and 10-8 M. The results obtained are shown
in Table I, taking into consideration the growth inhibitory
power (GI50).
Most of the susceptible tumors were generally inhibited
at micromolar concentration, expecially for the triazine 4d
bearing an ethoxycarbonyl functionality in position 10,
which generally resulted more active than 4c bearing a
carbamoyl group in the same position. Compound 4d gave
the best result in the leukemia and melanoma subpanels,
with GI50 values in the low micromolar range, 1.12-6.91 and
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2.09-5.97, respectively. The most sensitive cell lines were K-
562 (1.12 ÌM) and RPMI-8226 (1.54 ÌM) of the former
subpanel; UACC-257 (2.09 ÌM) and MALME-3M (2.10
ÌM) belong to the latter subpanel. Moreover, in some
ovarian cancer cell lines, IGROV1, OVCAR-3, OVCAR-5,
OVCAR-8 and CNS cancer cell lines, SF539, SNB19 and
U251, good values of GI50 were observed: 1.12-6.03 ÌM and
4.93-5.66 ÌM, respectively. Compound 4c showed
remarkable inhibitory activity only in the case of the CNS
subpanel, with the exception of the SF268 cell line, showing
GI50 in the range 1.17-3.31 ÌM, and the ovarian cancer cell
line IGROV1 with GI50 1.33 ÌM. In the other cell lines
compound 4c, with some exceptions when the potency was
at the same level as compound 4d, was one magnitude order
less active and, in the case of the leukemia and in most of
the colon cancer cell lines, not active at all.
In order to discern the mechanism of action of
pyrrolotriazines, we performed COMPARE computations
(15) on the NCI screening data, using [1,2,4]triazino[4,3-
a]indoles 4c,d as seed compounds. Both had a Pearson
Correlation Coefficient <0.5 (data not shown) against the
"Standard Agents" database, suggesting that they probably act
with a different mechanism from those of the Standard Agents
and make this class of compounds worthy of considerable
attention. It is our intention to undertake studies directed at
elucidating their biochemical mechanism of action.
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Cell lines 4c 4d Cell lines 4c 4d
Leukemia Melanoma
CCRF-CEM  >100 2.22 LOX IMVI 28.3 5.96
HL-60(TB) >100 2.15 MALME-3M 70.9 2.10
K-562  >100 1.12 M14 >100 5.97
MOLT-4 >100 4.40 SK-MEL-2 20.5 5.15
RPMI-8226 >100 1.54 SK-MEL-28 >100 5.85
SR >100 6.91 SK-MEL-5 74.3 5.53
Non-small cell lung UACC-257 99.7 2.09
A549/ATCC >100 10.5 UACC-62 19.9 2.42
EKVX 18.0 25.8 Ovarian cancer
HOP-62 17.3 68.8 IGROV1 1.33 1.12
NCI-H23 16.7 5.94 OVCAR-3 >100 5.20
NCI-H322M 62.4 14.5 OVCAR-4 >100 >100
NCI-H460 50.3 8.13 OVCAR-5 16.1 5.16
NCI-H522 28.8 6.21 OVCAR-8 13.9 6.03
Colon cancer SK-OV-3 21.9 67.0
COLO 205 >100 10.2 Renal cancer
HCC-2998 >100 34.0 786-0 21.0 4.85
HCT-116 31.1 29.3 A498 6.07 7.19
HCT-15 79.0 7.66 ACHN 32.8 7.49
HT29 >100 22.7 CAKI-1 16.1 >100
KM12 >100 4.43 RXF 393 >100 6.66
SW-620 >100 8.26 SN12C 11.3 7.90
CNS cancer  TK-10 74.3 7.87
SF-268 16.0 19.3 UO-31 59.9 5.35
SF-295 3.31 26.9 Breast cancer
SF-539 1.62 5.66 MCF7 17.6 13.1
SNB-19 1.93 4.93 NCI/ADR-RES 35.3 3.62
SNB-75 1.17 11.0 MDA-MB231/ATCC 18.7 19.8
U251 1.52 5.41 HS 578T 4.36 7.16
Prostate cancer MDA-MB-435 4.36 5.04
PC-3 59.9 53.5 MDA-N >100 4.35
DU-145 >100 37.4 BT-549 22.1 13.7
T-47D 43.0 30.0
aData obtained from NCI’s in vitro disease-oriented tumor cells screen. 
bGI50 is the molar concentration causing 50% growth inhibition of tumor cells. Compounds with GI50 >100 ÌM are considered inactive. 
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